( ) was the subject of a significant drop in short interest during March. On March 31, there were 300 shares of short interest, which is a significant drop from 1,500 shares on March 15. The days-to-cover is 0.1 days based on a trading volume average of 3,200 shares.
Biostage Stocks Up 4.1 %
Trading on Friday saw a $0.25 increase, bringing the price to $6.40. The average trading volume for the company was 2,181. The market cap is $78.14m, with a P/E ratio of -6.60. Its beta is -0.95. Biostage's 1-year low is $4.30, and its 1-year high is $9.00. Get Rating
Biostage, Inc. is a biotechnology firm that develops organ implants for the treatment of congenital defects, tumors, and life threatening conditions in the esophagus, the bronchus, and the trachea. Cellframe technology is used to activate the body's natural healing process and stimulate signaling pathways.
MarketBeat.com offers a FREE daily email newsletter